Teva Pharmaceutical is touting the results of a late-stage study of Azilect, a treatment for Parkinson's disease. Researchers say the therapy hit all of its goals in the ADAGIO trial. Patients taking a once-daily oral dose of the drug reported a slowing of disease progression early on in the trial with a reduction in symptoms at a later point in the trial. The drug is already approved for treating symptoms of the disease, but Teva is looking to add an approval for disease modification.
- read the AP report [1]
Related Articles:
Teva takes control of Azilect [2]
Gene therapy offers impressive results for Parkinson's [3]
Molecule could reverse Parkinson's [4]
Links:
[1] http://www.forbes.com/feeds/ap/2008/08/26/ap5357711.
[2] http://www.fiercebiotech.com/story/spotlight-teva-takes-control-of-azilect/2006-07-12
[3] http://www.fiercebioresearcher.com/story/gene-therapy-offers-impressive-results-parkinsons/2007-11-20
[4] http://www.fiercebioresearcher.com/story/molecule-could-reverse-parkinson-s/2007-07-17